(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Adial Pharmaceuticals's earnings in 2026 is -$7,977,171.On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$14,783,773, with the lowest ADIL earnings forecast at -$17,842,485, and the highest ADIL earnings forecast at -$11,320,232. On average, 4 Wall Street analysts forecast ADIL's earnings for 2027 to be -$13,108,765, with the lowest ADIL earnings forecast at -$18,192,338, and the highest ADIL earnings forecast at -$7,496,843.
In 2028, ADIL is forecast to generate -$830,222 in earnings, with the lowest earnings forecast at -$797,664 and the highest earnings forecast at -$854,640.